<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="361">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03250741</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2015-002965-43</org_study_id>
    <nct_id>NCT03250741</nct_id>
  </id_info>
  <brief_title>Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease</brief_title>
  <acronym>DOPAD</acronym>
  <official_title>Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease: a Phase II 24-week, Randomized, Double-blind Placebo Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I.R.C.C.S. Fondazione Santa Lucia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I.R.C.C.S. Fondazione Santa Lucia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is phase IIa 24-week, prospective, randomized, double-blind placebo controlled study.&#xD;
      The study is designed to evaluate the efficacy, safety, and tolerability of transdermal patch&#xD;
      of Rotigotine (RTG) versus placebo (PLC) as add-on therapy with AChEI in patients with mild&#xD;
      AD according to the consensus diagnostic criteria and MMSE score of ≥18 and ≤24 at screening.&#xD;
      Two groups of patients with mild AD will be involved (50 patients each). One group will be&#xD;
      assigned to treatment with RTG 4 mg and the other one to PLC as add on to AChEI therapy&#xD;
      (Rivastigmine). Clinical and neurophysiological measurements will be collected before and&#xD;
      after drug administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study has the ambition to provide first time evidence that dopaminergic&#xD;
      stimulation may have a clinical impact in patients with mild AD.&#xD;
&#xD;
      Cognitive Assessment: Before and after the 24 weeks of treatment the ADAS-Cog, ADCS-ADL and&#xD;
      the Frontal assessment battery (FAB) will be administered. FAB will be performed to measure&#xD;
      changes in frontal executive functions (Apollonio et al, 2005) .&#xD;
&#xD;
      Neurophysiological investigations will be performed to identify quantifiable biomarkers&#xD;
      underlying the effects induced by dopamine agonist on the neurodegenerative brain. The&#xD;
      application of recent neurophysiological tools, such as the combined use of transcranial&#xD;
      magnetic stimulation (TMS) during electroencephalography (EEG) will allow to measure how&#xD;
      dopamine agonists are able to modulate the cortical activity of the prefrontal cortex in AD&#xD;
      patients (Kähkönen et al., 2005; Julkunen et al., 2008), likely trough DA terminals&#xD;
      originating from the ventral tegmental nucleus, defining the neurophysiological biomarkers of&#xD;
      clinical improvement For EEG-TMS recordings, a TMS-compatible EEG equipment will be used for&#xD;
      recording EEG activity from the scalp (BrainAmp 32MRplus, BrainProducts). The EEG will be&#xD;
      continuously acquired from 64 scalp sites positioned according to the 10-20 International&#xD;
      System. To precisely position the coil over the cortical sites across different sessions, a&#xD;
      neuronavigation system (Softaxic, E.M.S.) will be used. Neurophysiological changes induced by&#xD;
      dopamine-agonist will be indexed by the following measures: corticospinal excitability,&#xD;
      cortical reactivity, connectivity and plasticity. Specifically, the cortical reactivity and&#xD;
      cortico-cortical connectivity will be evaluated respectively over the prefrontal cortex and&#xD;
      between connected areas. We will employ TMS-evoked cortical responses (i.e., TEPs) as a novel&#xD;
      probe of dopamine-agonist induced cortical excitability changes (Ilmoniemi et al., 1997;&#xD;
      Komssi and Kahkonen, 2006; Julkunen et al., 2008; Miniussi and Thut, 2009; Miniussi et al.,&#xD;
      2012; Premoli et al., 2014). To reach this aim, TEPs will serve as markers of left prefrontal&#xD;
      cortex (PFC) reactivity whereas the spreading of their cortical activation will serve as an&#xD;
      index of connectivity between targeted cortex and functionally connected areas underlying&#xD;
      frontal cognitive network.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global cognition</measure>
    <time_frame>change from baseline to Week 24</time_frame>
    <description>Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frontal cognitive functions</measure>
    <time_frame>change from baseline to Week 24</time_frame>
    <description>Frontal assessment battery (FAB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of daily living</measure>
    <time_frame>change from baseline to Week 24</time_frame>
    <description>Alzheimer's disease Cooperative Study - Activities of Daily Living (ADCS-ADL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurophysiological markers of cortical activity</measure>
    <time_frame>change from baseline to Week 24</time_frame>
    <description>TEP amplitude over the PFC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric evaluation</measure>
    <time_frame>change from baseline to Week 24</time_frame>
    <description>Neuropsychiatric Inventory (NPI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Rotigotine 4 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rotigotine transdermal patches 4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo transdermal patches</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rotigotine transdermal patch</intervention_name>
    <description>Rotigotine transdermal patches 4mg/24hr</description>
    <arm_group_label>Rotigotine 4 mg</arm_group_label>
    <other_name>ROTIGOTINE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo transdermal patches of the same size as for Rotigotine transdermal patches</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo transdermal patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient (or if applicable the legally acceptable representative if different from&#xD;
             the responsible caregiver) and the responsible caregiver have signed the Informed&#xD;
             Consent Form.&#xD;
&#xD;
          2. The patient has probable AD, diagnosed according to National Institute of Neurological&#xD;
             and Communicative Disorders and Stroke and the Alzheimer's Disease and Related&#xD;
             Disorders Association (NINCDS-ADRDA) criteria.&#xD;
&#xD;
          3. The patient is a man or woman, aged ≤ 85 years.&#xD;
&#xD;
          4. The patient has a Clinical Dementia Rating (CDR) total score of 0.5 or 1 (mild) and&#xD;
             MMSE score of 20-26 (inclusive) at Screening.&#xD;
&#xD;
          5. Has at least one identified adult caregiver who is able to provide meaningful&#xD;
             assessment of changes in subject behavior and function over time and provide&#xD;
             information on safety and tolerability, and is able to verify daily compliance with&#xD;
             study drug&#xD;
&#xD;
          6. The patient has been treated with acetylcholinesterase inhibitor (AChEI), i.e.,&#xD;
             donepezil, galantamine, or rivastigmine, at the time of Screening&#xD;
&#xD;
               -  For at least 3 months&#xD;
&#xD;
               -  The current dosage regimen and must have remained stable for ≥ 8 weeks&#xD;
&#xD;
               -  It must be planned that the dosage regimen will remain stable throughout&#xD;
                  participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant neurodegenerative disorder of the central nervous system other than&#xD;
             Alzheimer's disease, e.g., Lewy body dementia, Parkinson's disease, multiple&#xD;
             sclerosis, progressive supranuclear palsy, hydrocephalus, Huntington's disease, any&#xD;
             condition directly or indirectly caused by Transmissible Spongiform Encephalopathy&#xD;
             (TSE), Creutzfeldt-Jakob Disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), or&#xD;
             new variant Creutzfeldt-Jakob Disease (nvCJD)&#xD;
&#xD;
          2. The patients has history of seizure (with the exception of febrile seizures in&#xD;
             childhood)&#xD;
&#xD;
          3. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition - Text Revision&#xD;
             (DSM IV-TR) criteria met for any of the following within specified period:&#xD;
&#xD;
               -  Major depressive disorder (current)&#xD;
&#xD;
               -  Schizophrenia (lifetime)&#xD;
&#xD;
               -  Other psychotic disorders, bipolar disorder, or substance (including alcohol)&#xD;
                  related disorders (within the past 5 years)&#xD;
&#xD;
          4. Metal implants in the head (except dental), pacemaker, cochlear implants, or any other&#xD;
             non-removable items that are contraindications to MR imaging.&#xD;
&#xD;
          5. Evidence of clinically significant disease including but not limited to pulmonary,&#xD;
             gastrointestinal, renal, hepatic, endocrine, cardiovascular or metabolic disorder&#xD;
             (Patients with controlled diabetes, or hypertension, or complete/partial right bundle&#xD;
             branch block may be included in the study).&#xD;
&#xD;
          6. Treatment currently or within 6 months before Baseline with any of the following&#xD;
             medications:&#xD;
&#xD;
               -  Typical and atypical antipsychotics (i.e. Clozapine, Olanzapine)&#xD;
&#xD;
               -  Antiparkinson agents (e.g., levodopa, dopamine agonists, COMT inhibitors,&#xD;
                  amantadine, monoamine oxidase B inhibitors, anticholinergics etc)&#xD;
&#xD;
               -  Carbamazepine, Primidone, Pregabalin, Gabapentin&#xD;
&#xD;
               -  Memantine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Martorana, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Rome Tor Vergata</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giacomo Koch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Santa Lucia Foundation IRCCS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Santa Lucia Foundation</name>
      <address>
        <city>Rome</city>
        <zip>00179</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Martorana A, Di Lorenzo F, Esposito Z, Lo Giudice T, Bernardi G, Caltagirone C, Koch G. Dopamine D₂-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients. Neuropharmacology. 2013 Jan;64:108-13. doi: 10.1016/j.neuropharm.2012.07.015. Epub 2012 Aug 1.</citation>
    <PMID>22863599</PMID>
  </reference>
  <results_reference>
    <citation>Martorana A, Koch G. &quot;Is dopamine involved in Alzheimer's disease?&quot;. Front Aging Neurosci. 2014 Sep 25;6:252. doi: 10.3389/fnagi.2014.00252. eCollection 2014. Review.</citation>
    <PMID>25309431</PMID>
  </results_reference>
  <results_reference>
    <citation>Koch G, Di Lorenzo F, Bonnì S, Giacobbe V, Bozzali M, Caltagirone C, Martorana A. Dopaminergic modulation of cortical plasticity in Alzheimer's disease patients. Neuropsychopharmacology. 2014 Oct;39(11):2654-61. doi: 10.1038/npp.2014.119. Epub 2014 May 26.</citation>
    <PMID>24859851</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>August 11, 2017</study_first_submitted>
  <study_first_submitted_qc>August 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2017</study_first_posted>
  <last_update_submitted>December 14, 2018</last_update_submitted>
  <last_update_submitted_qc>December 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>I.R.C.C.S. Fondazione Santa Lucia</investigator_affiliation>
    <investigator_full_name>Giacomo Koch</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Rotigotine</keyword>
  <keyword>Dopamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotigotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

